期刊
BIOTECHNOLOGY ADVANCES
卷 35, 期 1, 页码 77-94出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biotechadv.2016.12.002
关键词
Induced pluripotent stem cells; Cardiac differentiation; Tissue engineering; Disease modeling; Drug screening
资金
- Wallace H. Coulter Foundation Translational Research Partnership Award
- Washington State Life Science Discovery Fund [LSDF 9749063]
- American Heart Association [AHA 13SDG14560076]
- NIH [1R21EB020132-01A1, RO1 HL117991, 2T32HL007312-36A1, 5T32EB001650-12]
- International Collaborative RD Program
- KIAT - MOTIE [N0000894]
- McEwen Centre for Regenerative Medicine
- Peter Munk Cardiac Centre
- Ontario Institute for Regenerative Medicine
- Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea [N0000894] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Improved methodologies for modeling cardiac disease phenotypes and accurately screening the efficacy and toxicity of potential therapeutic compounds are actively being sought to advance drug development and improve disease modeling capabilities. To that end, much recent effort has been devoted to the development of novel engineered biomimetic cardiac tissue platforms that accurately recapitulate the structure and function of the human myocardium. Within the field of cardiac engineering, induced pluripotent stem cells (iPSCs) are an exciting tool that offer the potential to advance the current state of the art, as they are derived from somatic cells, enabling the development of personalized medical strategies and patient specific disease models. Here we review different aspects of iPSC-based cardiac engineering technologies. We highlight methods for producing iPSC-derived cardiomyocytes (iPSC-CMs) and discuss their application to compound efficacy/toxicity screening and in vitro modeling of prevalent cardiac diseases. Special attention is paid to the application of micro- and nano-engineering techniques for the development of novel iPSC-CM based platforms and their potential to advance current preclinical screening modalities. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据